Trial Outcomes & Findings for The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels (NCT NCT03097484)

NCT ID: NCT03097484

Last Updated: 2019-05-14

Results Overview

How long the infant remains hospitalized.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

38 participants

Primary outcome timeframe

Up to 4 months

Results posted on

2019-05-14

Participant Flow

Participant milestones

Participant milestones
Measure
Standard Therapy ALONE
These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
Standard Therapy Plus Aromatherapy
These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy. lavender and chamomile essential oils: Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
Overall Study
STARTED
19
19
Overall Study
COMPLETED
19
19
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Standard Therapy ALONE
n=19 Participants
These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
Standard Therapy Plus Aromatherapy
n=19 Participants
These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy. lavender and chamomile essential oils: Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
Total
n=38 Participants
Total of all reporting groups
Age, Continuous
38.14 days
STANDARD_DEVIATION 9 • n=19 Participants
38.86 days
STANDARD_DEVIATION 5 • n=19 Participants
38.50 days
STANDARD_DEVIATION 7.28 • n=38 Participants
Sex: Female, Male
Female
10 Participants
n=19 Participants
11 Participants
n=19 Participants
21 Participants
n=38 Participants
Sex: Female, Male
Male
9 Participants
n=19 Participants
8 Participants
n=19 Participants
17 Participants
n=38 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
19 participants
n=19 Participants
19 participants
n=19 Participants
38 participants
n=38 Participants
Birth Weight
2.9 kilograms
STANDARD_DEVIATION 0.5 • n=19 Participants
3.1 kilograms
STANDARD_DEVIATION 0.4 • n=19 Participants
3.0 kilograms
STANDARD_DEVIATION .45 • n=38 Participants
Opioid Exposure Only
8 Participants
n=19 Participants
9 Participants
n=19 Participants
17 Participants
n=38 Participants
Multi-Drug Exposure
11 Participants
n=19 Participants
10 Participants
n=19 Participants
21 Participants
n=38 Participants

PRIMARY outcome

Timeframe: Up to 4 months

How long the infant remains hospitalized.

Outcome measures

Outcome measures
Measure
Standard Therapy ALONE
n=19 Participants
These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
Standard Therapy Plus Aromatherapy
n=19 Participants
These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy. lavender and chamomile essential oils: Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
Length of Hospitalization
17.8 days
Standard Deviation 10.1
11.4 days
Standard Deviation 6.6

SECONDARY outcome

Timeframe: Up to 4 months

How long the infant requires medication to treat symptoms.

Outcome measures

Outcome measures
Measure
Standard Therapy ALONE
n=19 Participants
These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
Standard Therapy Plus Aromatherapy
n=19 Participants
These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy. lavender and chamomile essential oils: Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
Length of Medication Therapy
12.7 days
Standard Deviation 10.1
7.4 days
Standard Deviation 6.1

Adverse Events

Standard Therapy ALONE

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standard Therapy Plus Aromatherapy

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

John Bauer, MD

University of Kentucky

Phone: 859-218-2927

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place